Trial Profile
A Multi-centre, Randomised, Double-blind, Placebo-controlled, Single Dose, Dose Escalation Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-0000-2021 Administered Intravenously and Subcutaneously to Healthy Male Subjects and Haemophilia Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 May 2019
Price :
$35
*
At a glance
- Drugs Concizumab (Primary) ; Concizumab (Primary)
- Indications Haemophilia
- Focus Adverse reactions
- Acronyms Explorer 1
- Sponsors Novo Nordisk
- 29 Apr 2014 New trial record